IMpower151
A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- NCT04194203 ↗
- Completed
- Hoffmann-La Roche
- Standard
We haven't built an HCP commentary report on IMpower151 (atezolizumab plus bevacizumab in chemotherapy-naïve stage IV non-squamous non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMpower151 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 9 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Atezolizumab; Placebo; Bevacizumab; Paclitaxel; Pemetrexed; Carboplatin
- Arms
- Treatment A · Experimental
- Treatment B · Placebo comparator
- Enrollment
- 305
- Primary outcomes
- Progression Free Survival (PFS) in the intent to treat (ITT) population, as determined by the investigator
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 9, 2020
- Primary completion
- Feb 2, 2023
- Results posted
- No
- Registry record
- NCT04194203 · updated Jul 19, 2024